Day One Biopharmaceuticals, Inc. Common Stock
DAWNDay One Biopharmaceuticals, Inc. (DAWN) is a clinical-stage biotechnology company focused on developing innovative therapies for rare and severe neurological disorders. The company leverages its proprietary gene therapy platform to address unmet medical needs, primarily targeting pediatric patients with neurodegenerative and neurogenetic conditions.
Company News
Day One Biopharmaceuticals (NASDAQ: DAWN) has successfully completed its acquisition of Mersana Therapeutics (NASDAQ: MRSN) for $25 per share in cash plus contingent value rights worth up to $30.25 per share. The acquisition adds Emi-Le, a novel antibody-drug conjugate targeting B7-H4 for treating adenoid cystic carcinoma, to Day One's clinical p...
Day One Biopharmaceuticals agreed to acquire Mersana Therapeutics for up to $285 million, expanding its oncology pipeline with a focus on developing antibody-drug conjugates targeting cancers, particularly in pediatric and triple-negative breast cancer treatments.
Day One Biopharmaceuticals announced it will acquire Mersana Therapeutics for approximately $129 million, expanding its oncology portfolio with the antibody-drug conjugate emiltatug ledadotin (Emi-Le), which shows early anti-tumor activity in adenoid cystic carcinoma treatment.
Day One Biopharmaceuticals reported Q2 2025 net product revenue of $33.6 million for OJEMDA, a 310% increase from Q2 2024. The company expects full-year 2025 revenue of $140-$150 million and continues advancing its clinical pipeline, including the FIREFLY-2 trial for pediatric low-grade glioma treatment.
The global cancer antibody drug conjugates (ADCs) market is expected to surpass $50 billion by 2030, driven by the approval of 16 ADC drugs and over 500 ADCs in clinical trials. The market has experienced substantial growth, reaching over $7 billion in the first half of 2024, with ADCs offering improved efficacy and lower toxicity compared to tra...
